Medical News

RSS

'New framework' needed to reduce slum expansion, new UN-HABITAT head says in speech outlining priorities

Joan Clos, the newly elected executive director of the U.N. Human Settlements Program (UN-HABITAT), on Tuesday urged the international community to focus on improving the lives of slum dwellers worldwide and take steps to reduce the expansion of slum areas, Xinhua/People's Daily Online reports.

8 Nov 2010

Inviragen to present data on CHIKV vaccine at ASTMH meeting

Inviragen, a biotechnology company developing vaccines to protect against infectious diseases worldwide, together with investigators at the University of Texas Medical Branch (UTMB) and the Division of Vector Borne Diseases (DVBD) of the Centers for Disease Control and Prevention, will make an oral presentation today at the annual American Society of Tropical Medicine and Hygiene (ASTMH) meeting on preclinical results of the Company's experimental chikungunya virus (CHIKV) vaccine.

8 Nov 2010

Oragenics awarded $733,437 Federal Grant under PPACA Act

Florida-based biopharmaceutical company Oragenics, Inc. announced that it will receive a $733,437 Federal Grant as part of Congress's Patient Protection and Affordable Care Act of 2010.

8 Nov 2010

FDA reviews GSK's response to Complete Response letter for Horizant

GlaxoSmithKline and XenoPort, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review GSK's response to FDA's Complete Response letter for Horizant (gabapentin enacarbil) Extended-Release Tablets. Horizant is under review for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

8 Nov 2010

Leaders discuss best practices, challenges for detecting counterfeit medications

During the opening of the 10th annual meeting of the International Society of Pharmacovigilance (ISoP) in Accra, Ghana, the country's "Vice President John Dramani Mahama on Wednesday called on member countries of the society to institute effective measures that would help detect fake and counterfeit drugs," Ghana News Agency reports.

8 Nov 2010

AHRQ grants $34 million to prevent healthcare-associated infections

HHS' Agency for Healthcare Research and Quality today announced the award of $34 million for projects focused on preventing one of the top 10 leading causes of death in the United States - healthcare-associated infections (HAIs). This new funding will help improve the quality of care delivered to patients and expand the fight against HAIs in hospitals, ambulatory care settings, end-stage renal disease facilities and long-term care facilities.

8 Nov 2010

ACTEMRA reduces signs, symptoms in patients with rheumatoid arthritis

Genentech, Inc., a member of the Roche Group today announced updated data from a Phase III study (ROSE) that showed rheumatoid arthritis (RA) patients receiving ACTEMRA (tocilizumab) experienced a rapid, measured response as early as one week after beginning ACTEMRA, and improvement in disease activity within four weeks.

8 Nov 2010

AccuVein receives QTDP grant for AV300 vein illumination system

AccuVein LLC, the developer of the first non-contact, handheld vein illumination system, announced today that it had been awarded the maximum grant amount from the Qualifying Therapeutic Discover Project (QTDP) program. This Federal grant program supports projects that show significant potential to produce new therapies, address unmet medical needs, and reduce the long-term growth of health care costs.

8 Nov 2010

How much did health care votes cause democratic defeats?

In the end, it may have mattered less whether vulnerable Democratic incumbents voted for or against the health care law than that they simply had a D by their names, The New York Times reports.

8 Nov 2010

Agios receives two grants under QTDP program to develop novel cancer metabolism therapies

Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced it has received two grants totaling more than $488,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program.

8 Nov 2010

EpiCept to receive $1.9 million in net proceeds

EpiCept Corporation announced today that it has entered into definitive agreements for the purchase of approximately 3.3 million shares of its common stock at $0.61 per share, and five-year warrants to purchase up to approximately 1.3 million shares of common stock at an exercise price of $0.56 per share, exercisable immediately.

8 Nov 2010

Report: FDA conflict-of-interest rules too restrictive

The conflict-of-interest policies in the medical profession are coming under fire as too stringent and as impeding medical progress, a claim the Food and Drug Administration dismisses as a misunderstanding of its rules.

8 Nov 2010

Researchers take first step towards understanding of rare skin cancer

Leeds-based scientists, funded by Yorkshire Cancer Research headquartered in Harrogate, North Yorkshire, plan to introduce the genetic material of a virus into normal human skin cells to produce skin cells that have features of Merkel Cell Carcinoma cancers.

8 Nov 2010

Eleven Biotherapeutics receives QTDP grants for lead protein-based discovery programs

Eleven Biotherapeutics, a biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics, today announced the receipt of three grants totaling more than $733,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program.

8 Nov 2010

Sanofi Pasteur's dengue vaccine enters phase III trial in Australia

Sanofi Pasteur, the vaccines division of the pharmaceutical group Sanofi-Aventis, on Thursday announced the company had begun testing its dengue fever vaccine in a Phase III clinical trial in Australia, Dow Jones/Wall Street Journal reports.

8 Nov 2010

Jasco receives grant under PPACA Act to develop therapeutics for cancer treatment

Jasco Pharmaceuticals, LLC was awarded a grant under the US Government's Patient Protection and Affordable Care Act (PPACA) of 2010. The grant was related to Jasco Pharma's novel small molecule Pim inhibitor program intended to develop therapeutics for the treatment of cancer.

8 Nov 2010

Genentech announces Phase II RG7204 clinical study results for metastatic melanoma tumors

Genentech, Inc., a member of the Roche Group today announced results from a Phase II clinical study of RG7204 (PLX4032), an investigational first-in-class molecule designed to selectively inhibit a cancer-causing, mutated form of the BRAF protein found in approximately half of metastatic melanoma tumors.

8 Nov 2010

Telegraph examines upcoming African mobile health summit

The Telegraph looks at the upcoming Mobile Health Africa Summit, the first event of its kind where stakeholders across Africa and the world will come together to debate the implementation of m-health across the continent.

8 Nov 2010

InNexus receives $116,760 cash grant under QTDP program to develop DXL anti-cancer antibodies

InNexus Biotechnology Inc. a leading drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL) technology, today announced it has been awarded a cash grant by the U.S. government totaling $116,760 for projects related to the Company's development of DXL anti-cancer antibodies.

8 Nov 2010

Deletion of 17q12 chromosomal region increases risk factor for ASD, schizophrenia

Researchers have identified the deletion of a genomic region on chromosome 17 as a significant risk factor for autism spectrum disorders (ASD) and schizophrenia. A mutation of one of the genes in the deleted interval already is a known cause of renal cysts and diabetes syndrome (RCAD).

8 Nov 2010

Medical News

'New framework' needed to reduce slum expansion, new UN-HABITAT head says in speech outlining priorities

Inviragen to present data on CHIKV vaccine at ASTMH meeting

Oragenics awarded $733,437 Federal Grant under PPACA Act

FDA reviews GSK's response to Complete Response letter for Horizant

Leaders discuss best practices, challenges for detecting counterfeit medications

AHRQ grants $34 million to prevent healthcare-associated infections

ACTEMRA reduces signs, symptoms in patients with rheumatoid arthritis

AccuVein receives QTDP grant for AV300 vein illumination system

How much did health care votes cause democratic defeats?

Agios receives two grants under QTDP program to develop novel cancer metabolism therapies

EpiCept to receive $1.9 million in net proceeds

Report: FDA conflict-of-interest rules too restrictive

Researchers take first step towards understanding of rare skin cancer

Eleven Biotherapeutics receives QTDP grants for lead protein-based discovery programs

Sanofi Pasteur's dengue vaccine enters phase III trial in Australia

Jasco receives grant under PPACA Act to develop therapeutics for cancer treatment

Genentech announces Phase II RG7204 clinical study results for metastatic melanoma tumors

Telegraph examines upcoming African mobile health summit

InNexus receives $116,760 cash grant under QTDP program to develop DXL anti-cancer antibodies

Deletion of 17q12 chromosomal region increases risk factor for ASD, schizophrenia

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News